The Thr92Ala 5′ Type 2 Deiodinase Gene Polymorphism Is Associated with a Delayed Triiodothyronine Secretion in Response to the Thyrotropin-Releasing Hormone-Stimulation Test: A Pharmacogenomic Study

被引：51

作者：

Butler, Peter W. ^{[1
,2
]}

Smith, Sheila M. ^{[1
]}

Linderman, Joyce D. ^{[1
]}

Brychta, Robert J. ^{[1
]}

Alberobello, Anna Teresa ^{[1
]}

Dubaz, Ornella M. ^{[1
]}

Luzon, Javier A. ^{[1
]}

Skarulis, Monica C. ^{[1
]}

Cochran, Craig S. ^{[1
]}

Wesley, Robert A. ^{[3
]}

Pucino, Frank ^{[1
]}

Celi, Francesco Saverio ^{[1
]}

机构：

[1] NIDDK, Clin Endocrinol Branch, NIH, Bethesda, MD 20892 USA

[2] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Reprod & Adult Endocrinol Branch, NIH, Bethesda, MD USA

[3] NIH, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA

来源：

THYROID | 2010年 / 20卷 / 12期

关键词：

IODOTHYRONINE DEIODINASE; INSULIN-RESISTANCE; THYROXINE; DIO2; 3,5,3'-TRIIODOTHYRONINE; 5'-DEIODINASE; PARAMETERS; THERAPY; VARIANT;

D O I：

10.1089/thy.2010.0244

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: The common Thr92Ala D2 polymorphism has been associated with changes in pituitary-thyroid axis homeostasis, but published results are conflicting. To investigate the effects of the Thr92Ala polymorphism on intrathyroidal thyroxine (T4) to triiodothyronine (T3) conversion, we designed prospective pharmacogenomic intervention aimed to detect differences in T3 levels after thyrotropin (TSH)-releasing hormone (TRH)-mediated TSH stimulation of the thyroid gland. Methods: Eighty-three healthy volunteers were screened and genotyped for the Thr92Ala polymorphism. Fifteen volunteers of each genotype (Thr/Thr, Thr/Ala, and Ala/Ala) underwent a 500 mcg intravenous TRH stimulation test with serial measurements of serum total T3 (TT3), free T4, and TSH over 180 minutes. Results: No differences in baseline thyroid hormone levels were seen among the study groups. Compared to the Thr/Thr group, the Ala/Ala group showed a significantly lower TRH-stimulated increase in serum TT3 at 60 minutes (12.07 +/- 2.67 vs. 21.07 +/- 2.86 ng/dL, p = 0.029). Thr/Ala subjects showed an intermediate response. Compared to Thr/Thr subjects, the Ala/Ala group showed a blunted rate of rise in serum TT3 as measured by mean time to 50% maximum delta serum TT3 (88.42 +/- 6.84 vs. 69.56 +/- 6.06 minutes, p = 0.028). Subjects attained similar maximal (180 minutes) TRH-stimulated TT3 levels. TRH-stimulated TSH and free T4 levels were not significantly different among the three genotype groups. Conclusions: The commonly occurring Thr92Ala D2 variant is associated with a decreased rate of acute TSH-stimulated T3 release from the thyroid consistent with a decrease in intrathyroidal deiodination. These data provide a proof of concept that the Thr92Ala polymorphism is associated with subtle changes in thyroid hormone homeostasis.

引用

页码：1407 / 1412

页数：6

共 22 条

[1] Polymorphisms in type 2 deiodinase are not associated with well-being, neurocognitive functioning, and preference for combined thyroxine/3,5,3′-triiodothyronine therapy [J].

Appelhof, BC ;

Peeters, RP ;

Wiersinga, WM ;

Visser, TJ ;

Wekking, EM ;

Huyser, J ;

Schene, AH ;

Tijssen, JGP ;

Hoogendijk, WJG ;

Fliers, E .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (11) :6296-6299

[2] Characterization of the 5′-flanking and 5′-untranslated regions of the cyclic adenosine 3′,5′-monophosphate-responsive human type 2 iodothyronine deiodinase gene [J].

Bartha, T ;

Kim, SW ;

Salvatore, D ;

Gereben, B ;

Tu, HM ;

Harney, JW ;

Rudas, P ;

Larsen, PR .

ENDOCRINOLOGY, 2000, 141 (01) :229-237

[3] Thyroid hormone receptors and type I iodothryronine 5′-deiodinase activity of human thyroid adenomas and benign cold nodules [J].

Brtko, J ;

Bobálová, J ;

Podoba, J ;

Schmutzler, C ;

Köhrle, J .

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2002, 110 (04) :166-170

[4] The type 2 deiodinase A/G (Thr92Ala) polymorphism is associated with decreased enzyme velocity and increased insulin resistance in patients with type 2 diabetes mellitus [J].

Canani, LH ;

Capp, C ;

Dora, JM ;

Meyer, ELS ;

Wagner, MS ;

Harney, JW ;

Larsen, PR ;

Gross, JL ;

Bianco, AC ;

Maia, AL .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (06) :3472-3478

[5] The role of type 1 and type 2 5′-deiodinase in the pathophysiology of the 3,5,3′-triiodothyronine toxicosis of McCune-Albright syndrome [J].

Celi, Francesco S. ;

Coppotelli, Giuseppe ;

Chidakel, Aaron ;

Kelly, Marilyn ;

Brillante, Beth A. ;

Shawker, Thomas ;

Cherman, Natasha ;

Feuillan, Penelope P. ;

Collins, Michael T. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (06) :2383-2389

[6]

Congedo Valentina, 2007, Pediatr Endocrinol Rev, V4 Suppl 4, P429

[7] The association of polymorphisms in the type 1 and 2 deiodinase genes with circulating thyroid hormone parameters and atrophy of the medial temporal lobe [J].

de Jong, Frank Jan ;

Peeters, Robin P. ;

den Heijer, Tom ;

van der Deure, Wendy M. ;

Hofman, Albert ;

Uitterlinden, Andre G. ;

Visser, Theo J. ;

Breteler, Monique M. B. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (02) :636-640

[8] The clinical impact of the thyrotropin-releasing hormone test [J].

Faglia, G .

THYROID, 1998, 8 (10) :903-908

[9] Ala92 type 2 deiodinase allele increases risk for the development of hypertension [J].

Gumieniak, Olga ;

Perlstein, Todd S. ;

Williams, Jonathan S. ;

Hopkins, Paul N. ;

Brown, Nancy J. ;

Raby, Benjamin A. ;

Williams, Gordon H. .

HYPERTENSION, 2007, 49 (03) :461-466

[10] Thr92Ala polymorphism in the type 2 deiodinase is not associated with T4 dose in athyroid patients or patients with Hashimoto thyroiditis [J].

Heemstra, K. A. ;

Hoftijzer, H. C. ;

van der Deure, W. M. ;

Peeters, R. P. ;

Fliers, E. ;

Appelhof, B. C. ;

Wiersinga, W. M. ;

Corssmit, E. P. M. ;

Visser, T. J. ;

Smit, J. W. A. .

CLINICAL ENDOCRINOLOGY, 2009, 71 (02) :279-283

← 1 2 3 →